The 6th Annual World ADC Asia 2027 brings together experts in antibody-drug conjugates (ADCs) to explore cutting-edge advancements in design, development, and clinical applications for oncology treatment.
Key Topics
Advancing ADC conjugation approaches for enhanced homogeneity and optimal drug substance quality
Developing and maintaining ADC CMC capability at high-scale production
Discovering and validating new ADC targets for unlocking new therapeutic potential
Optimizing clinical development strategies for ADCs to demonstrate early efficacy and inform dosing decisions
Assessing how novel format and payload conjugates can deliver more targeted and safer treatments to a wider patient population
Overcoming resistance with next-generation ADCs to reshape the future of oncology care
Showcasing pioneering ADC clinical development
Enhancing analytical methods and validation strategies to support ADC development and approval
Transitioning bispecific ADCs from concept to the clinic
Discovering and designing dual-payload ADCs to harness a two-pronged attack on tumor cells
Clinically validating novel biomarkers for improved patient selection with ADC drug-diagnostic co-development
Bridging the translational gap in ADCs by leveraging preclinical modeling and biomarkers
Exploring early learnings in the development of ADCs to supercharge the future of ADC design and development
Learning ADC chemistry basics – examining the role of payload, linker, and conjugation site in ADC design
Showcasing the latest game-changing data from the ADC world to reshape the oncology landscape
Introduction to ADCs seminar day
Overview of key biology considerations for ADC development
Bispecific ADC seminar day
Design principles for bispecific ADCs with optimal target affinity and internalization properties
Selecting and diversifying ADC payloads for overcoming tumor resistance, with optimized efficacy and safety
Who should attend
Oncology researchers and clinicians
ADC drug development specialists
Biopharmaceutical and biotech industry professionals
Regulatory and clinical development experts
Translational science and biomarker researchers
Pharmaceutical CMC and manufacturing professionals
Immuno-oncology and targeted therapy scientists
Preclinical and toxicology researchers
Bioconjugation and chemistry experts
Business development and licensing professionals in ADCs
